Lv3
340 积分 2025-01-20 加入
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
4小时前
待确认
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
4小时前
求助中
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
6天前
已完结
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
6天前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Development of Chinese innovative drugs in the USA
1个月前
已完结
From Challenges to Solutions: A Review of Fourth-Generation EGFR Tyrosine Kinase Inhibitors to Overcome the C797S Triple Mutation in Non-Small Cell Lung Cancer
2个月前
已完结
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
2个月前
已完结
皖公网安备34019202002308
